<DOC>
	<DOC>NCT00594308</DOC>
	<brief_summary>The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. This research is being done because there is no completely safe and effective prevention for graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after a transplant known as nonmyeloablative ("mini" transplant).</brief_summary>
	<brief_title>In-Vivo Activated T-Cell Depletion to Prevent GVHD</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Acute myelogenous leukemia, Acute lymphocytic leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Myelodysplasia, NonHodgkin's Lymphoma, Mantle cell, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis with diseasespecific eligibility requirements as outlined in the protocol Donor Requirement: Must have a fully HLAmatched (10 of 10) related or unrelated donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization and apheresis. Active CNS disease (the presence of leukemic blasts in the CSF) Pregnancy or breastfeeding SGOT &gt;3x upper limit of normal Creatinine &gt;2 or creatinine clearance &lt;50cc/hr. Fractional shortening by echocardiogram not within normal limits per institution Pulmonary function: DLCO less that 50% of normal predicted, corrected for anemia Prior allogeneic transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>